SCHEMBL1791204

SCHEMBL1791204

CC(C)c1nn(NC(=O)Cc2cc(F)cc(F)c2)c(=O)c2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NLRP3 Q96P20 2/20 0.41
▸ PSEN1 P49768 12/20 0.41
▸ PSEN2 P49810 12/20 0.41
▸ APH1B Q8WW43 12/20 0.41
▸ NCSTN Q92542 12/20 0.41
▸ APH1A Q96BI3 12/20 0.41
▸ PSENEN Q9NZ42 12/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ USP2 O75604 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ GSAP A4D1B5 1/20 0.39
▸ AKR1B1 P15121 1/20 0.39
▸ POLB P06746 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ NR2F2 P24468 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ SIGMAR1 Q99720 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30814194 1.00 NLRP3 (0.41) NLRP3PSEN1PSEN2APH1BNCSTN
SCHEMBL1786512 0.85 KMT2A (0.48) SMN1; SMN2USP2LMNAAKR1B1POLB
SCHEMBL30795566 0.85 KMT2A (0.48) SMN1; SMN2USP2LMNAAKR1B1POLB
SCHEMBL30796371 0.83 LMNA (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1784445 0.83 LMNA (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1787852 0.83 HPGD (0.52) SMN1; SMN2LMNAAKR1B1HTT
SCHEMBL1789011 0.83 TRPV1 (0.41) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL30796852 0.83 TRPV1 (0.41) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL30796507 0.81 TRPV1 (0.42) SMN1; SMN2USP2LMNAAKR1B1POLB
SCHEMBL30796353 0.81 MAPT (0.50) SMN1; SMN2USP2LMNAAKR1B1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629143-B2 Potassium channel modulators ABBVIE INC. (US) 2014-01-14 — — US claimed
EP-2504317-A1 POTASSIUM CHANNEL MODULATORS Abbott Laboratories (US) 2012-10-03 — — EP claimed
WO-2011066168-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-06-03 — — WO claimed
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-05-26 — — US claimed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 — — WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 — — WO disclosed
US-8629143-B2 Potassium channel modulators ABBVIE INC. (US) 2014-01-14 — — US disclosed
EP-2504317-A1 POTASSIUM CHANNEL MODULATORS Abbott Laboratories (US) 2012-10-03 — — EP disclosed
WO-2011066168-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-06-03 — — WO disclosed
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNQ3 NLRP3 1371/4885PSEN1 502/4885PSEN2 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback